Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti PD-L1 monoclonal antibody - Dragonboat Biopharmaceutical

Next Previous
Drug Profile

Anti PD-L1 monoclonal antibody - Dragonboat Biopharmaceutical

Alternative Names: LDP; LDP - Dragonboat Biopharmaceutical; Whole human form anti-PD-L1 antibody - Dragonboat Biopharmaceutical

Latest Information Update: 24 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dragonboat Biopharmaceutical
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Penile cancer; Renal cell carcinoma

Most Recent Events

  • 24 Jan 2023 Anti PD-L1 monoclonal antibody is still in phase II clinical trial in Renal cell carcinoma, Penile cancer, Bladder cancer in China
  • 11 Sep 2020 Phase-II clinical trials in Bladder cancer in China (IV) (NCT04718584)
  • 11 Sep 2020 Phase-II clinical trials in Penile cancer (Late-stage disease) in China (IV) (NCT04718584)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top